Hospital Cost Pressure: New data show prescription drug prices falling 3.1% while hospital prices rose 5.2%, pushing experts to argue lawmakers should tackle hospital spending growth with more transparency and competition—not just drug pricing. Food as Medicine: MarketsandMarkets projects the “food as medicine” market will jump from $254.15B (2026) to $400.81B by 2031, driven by functional foods and preventive nutrition. Cancer Care Support: The Friends of St Cross backed expansion of a breast cancer unit, adding equipment and growing staffing to handle about 500 patients a year. Air Quality Rules: Warwick District Council is consulting on updates to “smoke control areas,” aiming to modernize how solid-fuel burning is regulated. Peptide Regulation: An International Peptide Society leader says FDA’s advisory panel moved some peptides toward the 503A bulks list, but formal rulemaking and access limits remain. Cell & Gene Therapy Bottlenecks: Industry voices point to access, delivery, manufacturing complexity, and reimbursement as the biggest blockers. Immunization Policy Fight: RFK Jr. questions U.S. vaccine guideline categories as the administration pushes to split MMR into separate visits. Medical Devices Update (India): India’s health ministry eased sterilization licensing for outsourced device sterilization and added the EU to recognized jurisdictions for certain clinical investigation waivers. Obesity Pipeline Expansion: Genentech adds Hanmi’s HM17321 to broaden personalized obesity options, aiming to preserve muscle while driving fat loss. New Diagnostic Option (Wales): Wales rolls out a capsule sponge test for oesophageal cancer risk assessment, reducing reliance on sedated endoscopy and easing waiting lists. Healthcare Affordability (California): California considers penalties for hospitals and other providers that exceed state healthcare spending growth targets. Pharma Tariff Uncertainty (India-US): Indian generic makers are unlikely to rapidly shift U.S. production despite looming Trump tariff threats, citing low-margin economics and scale realities.